What the research shows
Muscle loss on GLP-1s: what the evidence shows
Sources verified against the primary documents on 9 July 2026.
The short answer
Lean mass does fall. A 2026 systematic review and meta-analysis of seven studies found an absolute lean-mass loss of about 1.74 kg on GLP-1 receptor agonists — and, in the same analysis, lean mass rose by 1.81% as a proportion of total body weight. Both are true: you lose muscle, and you lose more fat. Whether that costs you function has not been well measured, and the heterogeneity between studies is severe.
Key facts
- Absolute lean mass change
- −1.74 kg (95% CI −3.04 to −0.45)
- Lean mass as % of body weight
- +1.81% (95% CI 1.10 to 2.52)
- Semaglutide, absolute lean mass
- −5.44 kg
- Between-study heterogeneity
- I² = 98% — very high
Two true statements that sound contradictory
A 2026 systematic review and meta-analysis of seven studies (821 patients) reported both of the following. On GLP-1 receptor agonists, absolute lean mass fell by 1.74 kg. And lean mass as a proportion of total body weight rose by 1.81%.
These are not in conflict. If you lose 15 kg, of which 12 kg is fat and 3 kg is lean tissue, your absolute lean mass has dropped and your body composition has improved. Every headline about GLP-1 muscle loss, and every rebuttal to it, is choosing one of these two numbers.
Losing lean mass during weight loss is not unique to these drugs. It happens with dieting, with bariatric surgery, and with any substantial energy deficit. The relevant question is whether it happens *more* on GLP-1s, and whether it matters.
Why the numbers are shakier than they look
The heterogeneity in that meta-analysis is I² = 98% for the absolute lean-mass estimates. That is close to the maximum. It means the seven studies disagreed with each other so profoundly that the pooled average is a summary of disagreement rather than a stable estimate of an effect. The semaglutide subgroup showed −5.44 kg; other estimates were far smaller.
A precise-looking confidence interval sitting on top of I² = 98% deserves to be read with suspicion, and a page that quotes the pooled figure without the heterogeneity is not telling you the whole thing.
"Lean mass" as measured by DXA is also not "muscle". It includes water, connective tissue, and organ mass. Rapid weight loss shifts fluid. Some of the measured lean-mass decline is not contractile tissue at all.
Nobody has measured the thing that matters most
The outcome people care about is strength and physical function, not a DXA compartment. The trials in this literature largely did not measure it. That is a gap in the evidence, not a reassurance.
What reasonably follows
Protein intake and resistance training are the standard countermeasures during any energy deficit, and they are not controversial. What is not established — because it has not been trialled properly in this population — is how much of the lean-mass loss they prevent on a GLP-1 specifically, or whether preventing it changes any outcome.
The most defensible reading is: lean mass declines, the magnitude is genuinely uncertain, body composition on the whole improves, and the functional consequences are unmeasured. That is less satisfying than either "GLP-1s destroy your muscle" or "muscle loss is a myth", and it is what the evidence supports.
Compounds referenced in this guide
Semaglutide is used or studied for weight loss; glycemic control and related fat loss and metabolic health goals. Potential benefits and safety depend on indication, formulation, dose, and medical supervision.
Tirzepatide is used or studied for significant weight loss; glucose control and related fat loss and metabolic health goals. Potential benefits and safety depend on indication, formulation, dose, and medical supervision.
Frequently asked questions
Do GLP-1 drugs cause muscle loss?
They cause lean-mass loss, as does any substantial weight loss. A 2026 meta-analysis found an absolute reduction of about 1.74 kg in lean mass, alongside a 1.81% increase in lean mass as a proportion of body weight. The between-study heterogeneity was very high (I² = 98%), so the absolute figure is unstable.
Is lean mass the same as muscle?
No. Lean mass as measured by DXA includes water, connective tissue, and organ mass alongside skeletal muscle. Rapid weight loss shifts body water, so part of a measured lean-mass decline is not contractile tissue.
How much protein should I eat on a GLP-1?
That is a clinical and nutritional question, and it depends on your body size, activity, and kidney function — ask a clinician or a dietitian. What the evidence supports generally is that adequate protein and resistance training attenuate lean-mass loss during any energy deficit. How much they help specifically on a GLP-1 has not been well studied.
Does GLP-1 muscle loss make you weaker?
The trials largely did not measure strength or physical function, so this is unknown. That is a gap in the evidence rather than evidence of no effect. It is worth noting the parallel with growth hormone secretagogues, where increased lean mass produced no measurable improvement in strength either.
Sources
Every link below was checked and resolved before publication. Where a claim could not be traced to a primary document, we left it out.
- Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: a systematic review and meta-analysis. Int J Obes. 2026
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025
Written by Pepperz Editorial and not medically reviewed — see our editorial standards. Educational reference only. Pepperz does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing recommendations.